The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the ...

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE ...

Novant Health Inc. pitch to investors features two ambitious initiatives: the first: tripling annual revenue from $10 billion ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...